| Similar Articles |
|---|
 |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C.   |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
January 14, 2009
Brian Orelli |
ZymoGenetics, the Pharmaceutical Zombie ZymoGenetics deal with Bristol-Myers may bring the drug developer stumbling back from the dead. |
The Motley Fool
January 13, 2012
Sean Williams |
CEO Gaffe of the Week: Bristol-Myers Squibb Some days, CEOs would be better off staying in bed. |
The Motley Fool
May 16, 2007
Mike Havrilla |
ZymoGenetics Is Poised to Stop Bleeding With shares of ZymoGenetics currently trading near three-year lows, now may be a good time to pick some up. |
BusinessWeek
February 26, 2007
Arlene Weintraub |
The Power Of The Pipeline Bristol-Myers Squibb is beset with troubles, but its new-drug potential makes it a target. |
The Motley Fool
November 6, 2006
Brian Lawler |
One Step at a Time ZymoGenetics' management is still facing challenges, but so far it has proved itself worthy to investors. |
The Motley Fool
August 21, 2009
Brian Orelli |
ZymoGenetics Goes in for the Kill ZymoGenetics went on the offensive, asking the Food and Drug Administration to pull competitor King Pharmaceuticals' Thrombin-JMI off the market. |
The Motley Fool
June 3, 2011
Brian Orelli |
Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up. |
Bio-IT World
May 19, 2004
Barbara Depompa |
Surging in Seattle Laid-back coastal-mountain lifestyle bolsters Northwestern biotech company. |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
The Motley Fool
April 29, 2004
Bill Mann |
Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
June 21, 2010
Luke Timmerman |
Bristol-Myers Dumps Exelixis Drug There is an exit payment for Exelixis. |
The Motley Fool
May 1, 2007
Mike Havrilla |
Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc. |
The Motley Fool
April 28, 2011
Brian Orelli |
1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix. |
BusinessWeek
January 29, 2007
Arlene Weintraub |
More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl. |
The Motley Fool
September 6, 2006
Brian Lawler |
Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
November 5, 2008
Brian Orelli |
ZymoGenetics Leads With Its Chin It says a lot about ZymoGenetics' quarter that management decided to open its conference call talking about its hepatitis C drug still in trials, rather than the sales results of its blood-clotting agent, Recothrom. |
The Motley Fool
October 26, 2007
Billy Fisher |
A Quarter to Boast About at Bristol Bristol-Myers announces a 22% rise in third-quarter revenue as Plavix sales continue to rise. Investors, take note. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
The Motley Fool
January 28, 2011
Brian Orelli |
Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
December 18, 2007
Brian Orelli |
Bristol-Myers' Sleeker Image Just 12 days after announcing its restructuring plan, Bristol-Myers Squibb has found a buyer for its medical-imaging division and plans to close the deal by the end of next month. |
The Motley Fool
May 28, 2008
Brian Lawler |
A Little-Noticed Drug Rejection The EU temporarily blocks Sanofi and Bristol-Myers' shot at extending a drug's lifespan. |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
The Motley Fool
July 12, 2004
Brian Gorman |
India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers. |
The Motley Fool
November 30, 2004
Charly Travers |
Picking Biotech's Winners Doing well as a biotech investor comes as much from avoiding the losers as picking the winners. A quick screen for making winning investment picks. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
January 18, 2008
Brian Orelli |
The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA. |
The Motley Fool
July 30, 2007
Brian Lawler |
Bristol-Myers Isn't Standing in Place Brighter days seem ahead for Bristol-Myers Squibb, now that recent litigation has taken a major turn for the better. |
